Seattle Cancer Care Alliance (SCCA) provides comprehensive, leading-edge treatment for people diagnosed with kidney cancers, including renal cell carcinoma, which accounts for 90 percent of kidney tumors in adults.
Genetic changes can be used to help diagnose cancer, understand the risk of recurrence and outlook for survival, and guide therapy decisions. SCCA has a new chromosome genomic array test called OncoScan CGAT to help identify these changes in people specifically with kidney cancer.
Most kidney cancers are initially treated with surgery. Advanced kidney cancer that has returned after surgery or spread to other organs is difficult to treat. But there is hope with biologic therapy, or immunotherapy, as well as a new generation of targeted therapies. Often the best treatment for kidney cancer is participation in a clinical trial.
Kidney Cancer Multispecialty Clinic
If you have metastatic kidney cancer, you may have your first appointment at the Kidney Cancer Multispecialty Clinic (KCMC) at SCCA. Your care will begin with a team evaluation with a urologic oncologist, medical oncologist, radiation oncologist, pathologist, radiologist, and resident doctor or fellow. All are UW Medicine doctors who specialize in kidney cancer. With our multispecialty approach, you will have the opportunity to discuss all aspects of your proposed treatment plan on the same day with each individual treating doctor. You will leave with all of your questions answered and a plan of care that is designed specifically for you and your needs.
Doctors and Surgeons with Leading-Edge Expertise
SCCA was formed in part to bring promising new treatments to patients faster. For people with kidney cancer, this means more treatment options at SCCA than you might find elsewhere, including the chance to participate in one of the clinical trials conducted at SCCA and its founding organizations, Fred Hutch and UW Medicine.